BASF successfully started up the world’s first production plant for catalysts based on its proprietary X3D® technology at its Ludwigshafen site. With this commissioning, the company is scaling additive manufacturing of catalysts to an industrial level. As a result, BASF is reinforcing its leadership in delivering innovative, high-performance solutions for the global chemical industry.

X3D Technology Enhances Performance and Efficiency

By leveraging X3D technology, BASF can design catalysts with optimized geometries that combine high mechanical stability with an open structure. Consequently, these advanced designs significantly reduce pressure drop within reactors while increasing the catalytically active surface area. In turn, customers benefit from higher reactor throughput and improved product quality. Moreover, the technology enables substantially lower energy consumption compared to conventional catalyst systems, making it both economically and environmentally advantageous.

Proven Technology with Broad Application Scope

Importantly, X3D technology is not new to the market. BASF has already been supplying X3D catalysts to both internal and external customers for several years. The technology has demonstrated strong performance across diverse industrial applications. X3D is highly versatile. It can be applied to a wide range of catalyst materials, including precious metals, base metals, and various support structures. With the new plant now operational, BASF can expand access to this technology while also accelerating development cycles and reducing time-to-market for new catalyst solutions.

Successful Industrial Deployment in China

A recent example highlights the tangible benefits of X3D catalysts. In 2025, the Chinese fine chemical company An Hui Jintung implemented BASF’s sulfuric acid catalysts O4-115 X3D in its production facility. According to Eter Zhu, General Manager at An Hui Jintung, the plant startup proceeded smoothly. Subsequently, performance improved significantly compared to previous operations. The company achieved record production levels, resulting in substantial economic gains. Encouraged by these outcomes, An Hui Jintung plans to further expand its collaboration with BASF to upgrade catalysts across additional units.

Driving Competitive Advantage Through Innovation

BASF emphasizes that X3D technology provides customers with a clear competitive edge. By enabling the production of catalysts tailored precisely to specific chemical processes, the company ensures faster delivery and scalability at industrial volumes.

At the same time, these advanced catalysts help customers meet key operational goals. They enhance production efficiency while optimizing raw material usage—an increasingly critical factor in today’s cost- and sustainability-driven environment.

Detlef Ruff, Senior Vice President Chemical Catalysts and Adsorbents at BASF, noted that the technology already delivers measurable value by improving performance and resource efficiency. Looking ahead, Yaqian Liu, who will succeed Ruff, expressed enthusiasm about leading a business that plays a crucial role in enabling chemical reactions and driving innovation.

Strengthening BASF’s Innovation Leadership

As per the press release, the launch of the pioneering facility marks a significant step forward in catalyst manufacturing. By combining additive manufacturing with advanced chemical engineering, BASF is not only transforming catalyst design but also setting new benchmarks for efficiency, sustainability, and industrial performance.

Photo: BASF

Clariant is strengthening its footprint in the North American pharmaceutical sector by expanding its Clear Lake facility in Texas. The upgrade will introduce excipient GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients. As a result, the company aims to significantly enhance product availability and supply reliability for customers across North America, while also extending support to Latin American markets. Importantly, this multi-phase expansion directly addresses critical industry concerns such as supply chain security, continuity, and responsiveness. At the same time, it reinforces Clariant’s long-term commitment to the U.S. pharmaceutical market.

First Dedicated U.S. Site for Pharma-Grade PEG

With this development, the Clear Lake facility becomes Clariant’s first U.S.-based manufacturing site dedicated to pharmaceutical-grade PEG excipients. This marks a key milestone in the company’s broader healthcare growth strategy. By establishing regional production capabilities, Clariant is not only localizing its operations but also building a more resilient and responsive supply chain. Consequently, pharmaceutical manufacturers in the region will benefit from improved access to high-quality excipients.

Operational Benefits for Pharmaceutical Manufacturers

The expansion is designed to deliver clear, tangible advantages to customers. For instance, regional manufacturing will significantly reduce lead times, enabling faster response to fluctuating market demand. In addition, shorter supply chains help lower inventory carrying costs and improve overall cost efficiency. Moreover, enhanced supply continuity ensures greater predictability—an essential factor for pharmaceutical companies managing complex production schedules and strict regulatory requirements. Therefore, customers can expect improved business continuity and operational stability.

Strengthening Customer Partnerships

Vaios Barlas, Head of Health Care at Clariant, emphasized the strategic importance of the expansion. “This expansion strengthens our ability to provide reliable local supply and positions us as a true partner to the North American pharmaceutical industry. In addition to greater manufacturing capacity, we are transforming how we serve our customers by bringing production closer to their operations and enabling more responsive, collaborative relationships,” Barlas said.

Compliance with Global Quality Standards

Equally important, the upgraded Clear Lake facility has been designed to meet the pharmaceutical industry’s most stringent quality, safety, and regulatory standards. The excipient GMP compliance ensures that all manufacturing processes align with internationally recognized pharmaceutical excipient guidelines. Clariant’s pharmaceutical-grade PEGs are registered in relevant pharmacopoeias and offer negligible toxicity profiles. This makes them suitable for a wide range of pharmaceutical applications while providing customers with the necessary documentation, traceability, and quality assurance required for regulated production.

A Step Toward Supply Chain Resilience

As per the press release, overall, the expansion reflects a broader industry shift toward regionalization and supply chain resilience. By investing in local manufacturing infrastructure, Clariant is positioning itself to better support pharmaceutical companies with reliable, high-quality excipients—exactly when and where they are needed.

Henkel announced the launch of its new Customer Application Center in Bengaluru, strengthening its commitment to India’s fast-growing electronics manufacturing ecosystem. The state-of-the-art facility is designed as a collaborative innovation hub where Henkel’s experts and customers can co-develop, test, and validate advanced adhesive and thermal management solutions for next-generation electronics.

Strengthening Local Innovation Capabilities

With this launch, Henkel is making one of its most significant application engineering investments in the India, Middle East, and Africa (IMEA) region. More importantly, the center addresses a long-standing gap in India’s electronics value chain—the lack of localized, world-class testing and validation infrastructure. As a result, manufacturers can now develop, qualify, and scale advanced materials solutions within India itself, eliminating the delays and high costs associated with sending projects overseas.

Riding the Wave of India’s Electronics Boom

India’s electronics manufacturing sector has expanded nearly six-fold over the past decade. Furthermore, this growth continues to accelerate, driven by key sectors such as Data centers and AI computing infrastructure, 5G and fiber network expansion, Electric vehicle (EV) charging systems, Industrial automation and advanced medical devices. Each of these industries relies heavily on high-performance adhesives, thermal management materials, and protective coatings. Consequently, the demand for faster, localized application engineering support has never been greater.

Why Bengaluru is the Ideal Location

Bengaluru naturally emerged as the preferred location for this advanced facility. The city hosts a dense concentration of semiconductor design talent, electronics R&D centers, and global OEM engineering teams. By establishing the center here, Henkel positions its expertise directly alongside the engineers and manufacturers who are driving innovation in India’s electronics ecosystem.

Leadership Perspective

Sunil Kumar, Country President – India, Henkel, highlighted, “India’s electronics manufacturing ecosystem is at a critical inflection point, with Bengaluru at its core. Manufacturers increasingly require not just high-quality materials, but also a local partner capable of co-developing, testing, and validating solutions under real production conditions. This center is designed to accelerate the journey from concept to commercialization while reinforcing Henkel’s long-term commitment to India”.

Facility Overview and Capabilities

The 5,000 sq. ft. facility includes approximately 2,400 sq. ft. of dedicated laboratory and testing space. Notably, it has been designed to replicate real-world electronics manufacturing environments, enabling customers to optimize materials and processes before scaling up production.

Supporting Make in India and Faster Time-to-Market

The new center aligns closely with India’s Make in India and Production-Linked Incentive (PLI) initiatives. By bringing application engineering, process optimization, and reliability validation onshore, Henkel enables manufacturers to operate more efficiently. Previously, many Indian companies had to rely on overseas facilities—or delay critical testing altogether. Now, they can complete these processes locally, significantly reducing development cycles and accelerating time-to-market.

A Collaborative Co-Innovation Model

What truly sets this facility apart is its collaborative approach. Henkel’s application experts will work closely with customer engineering teams, co-developing solutions tailored to specific device architectures and manufacturing requirements. As per the press release, the hands-on partnership transforms the center from a conventional testing lab into a dynamic co-innovation platform—one that is poised to play a pivotal role in advancing India’s electronics manufacturing capabilities.

Andhra Petrochemicals Limited (APL) announced the immediate suspension of operations at its primary manufacturing facility in Visakhapatnam. The shutdown follows a critical disruption in the supply of propylene, a key raw material, after Hindustan Petroleum Corporation Ltd (HPCL) halted deliveries. As a result, APL has stated that plant operations will remain suspended until feedstock supplies are restored.

Geopolitical Tensions Disrupt Energy Supply Chains

The supply disruption stems from escalating geopolitical tensions involving Iran, the United States, and Israel. Consequently, global and domestic energy supply chains have come under strain. These disruptions are now cascading into downstream industries, including petrochemicals and the automotive sector.

Impact on Oxo-Alcohol Production and Auto Chemicals

APL’s shutdown directly affects the production of oxo-alcohols, such as 2-ethylhexanol and normal butanol (n-butanol). These chemicals serve as essential building blocks in the automotive value chain. They are widely used in plasticizers, paints and coatings, fuels and lubricants, fluid systems Therefore, the suspension is expected to create a supply-side squeeze for auto-component manufacturers.

Supply Chain Pressure on Automotive Sector

As the disruption continues, automotive manufacturers may face rising input costs and production challenges. Since many auto-component producers rely on consistent domestic supply of these chemicals, any prolonged shutdown could disrupt production timelines and affect OEM deliveries.

Broader Industry Impact and Refinery Linkages

Industry analysts are closely tracking similar disruptions across the petrochemical sector. For instance, Tamilnadu Petroproducts Limited (TPL) has reportedly encountered comparable logistical challenges. The trend highlights a broader vulnerability: Indian chemical manufacturers remain heavily dependent on refinery-linked feedstocks. Consequently, disruptions at the refinery level—such as those impacting Hindustan Petroleum Corporation Ltd—quickly ripple through downstream chemical production.

Risk of Localized Shortages and Delayed Deliveries

The ongoing production halt not only threatens APL’s delivery schedules but also raises the risk of localized shortages in key industries, including automotive, textiles, fertilizers, and healthcare. If the situation persists, supply constraints could intensify, further impacting industrial output and pricing across sectors.

Outlook: Need for Supply Chain Resilience

The disruption underscores the urgent need for greater supply chain resilience in India’s petrochemical and manufacturing sectors. As reported by autocarpro.in, diversifying feedstock sources and strengthening domestic integration will be critical to mitigating the impact of future geopolitical and energy-related shocks.

thyssenkrupp nucera has been commissioned by Juno Joule Green Energy Private Ltd. to carry out a Front-End Engineering and Design (FEED) study for a 260 MW water electrolysis plant in India. The development marks a significant step forward in advancing large-scale green hydrogen production in the country.

Project to Focus on Green Hydrogen and Ammonia Production

Juno Joule plans to produce green hydrogen using water electrolysis. The hydrogen will then be converted into green ammonia, primarily targeting export markets in Europe. As a result, the project aligns with global efforts to decarbonize industries and expand clean energy supply chains.

Pathway Towards EPF Contract and Project Execution

Following the FEED study, thyssenkrupp nucera will collaborate closely with Juno Joule to progress the project towards the signing of an Engineering, Procurement, and Fabrication (EPF) contract. This phase will be critical in defining technical specifications, optimizing design, and preparing the groundwork for full-scale project execution.

Final Investment Decision Expected by FY 2026–27

The project’s execution will depend on a Final Investment Decision (FID), which is expected to be taken in the fiscal year 2026–27. If approved, the project will contribute significantly to India’s growing green hydrogen ecosystem while strengthening its position as a global supplier of sustainable fuels.

Strengthening India’s Green Energy Transition

As per the press release, the collaboration highlights increasing momentum in India’s renewable energy sector. By combining advanced electrolysis technology with export-oriented green ammonia production, the project is set to support both energy transition goals and international decarbonization efforts.

CropLife India released a Myth-versus-Fact explainer on pesticides, aiming to address growing public concerns around food residues, environmental risks, and product safety in India. The industry body noted that while concerns over misuse are valid and require attention, misinformation often distorts the realities faced by farmers in protecting crops from pests and diseases.

Agriculture’s Critical Role in India’s Economy

Agriculture remains a cornerstone of India’s economy, supporting over 93 million households and around 150 million farmers. Moreover, the sector employs nearly 46% of the workforce and contributes approximately 16–18% to the national GDP. However, crop losses remain a major challenge. According to government estimates, pests and diseases destroy 10–35% of crops annually, with even higher losses during severe outbreaks.

Low Pesticide Usage Compared to Global Levels

Despite these challenges, India continues to be among the lowest users of pesticides per hectare globally. Farmers in India typically use 0.3–0.6 kg per hectare, significantly lower than 2–4 kg in many European countries, around 13 kg in China, and over 10 kg in parts of East Asia. Therefore, the organisation emphasized that public discourse must reflect these realities while acknowledging the need for responsible usage and regulatory oversight.

Call for Evidence-Based and Balanced Debate

According to Durgesh Chandra, Secretary General, CropLife India, the objective of the explainer is to encourage a balanced and evidence-based conversation on crop protection. He highlighted that crop protection products play a vital role in safeguarding yields and ensuring food security. At the same time, the industry strongly supports responsible use, farmer awareness, and adherence to India’s regulatory framework.

Addressing Misconceptions Around Pesticides

CropLife India pointed out that common misconceptions—such as pesticides being widely overused or poorly regulated—often overlook India’s relatively low consumption levels and its structured approval system. To address this, the explainer clarifies key issues related to pesticide safety, residue management, environmental impact and regulatory controls. It relies on scientific evidence and official data to present a fact-based perspective.

Focus on Farmer Training and Sustainable Practices

The organisation stressed the importance of farmer training, improved stewardship practices, and continuous regulatory vigilance. These measures are essential to ensure that crop protection remains both safe and effective, while also supporting long-term agricultural sustainability.

Commitment to Sustainable Agriculture

CropLife India reaffirmed its commitment to supporting farmers, promoting best practices, and contributing to sustainable agriculture in India. As per the press release, the initiative aims to bridge the gap between perception and reality, fostering informed decision-making and strengthening trust in crop protection practices.

India’s chemicals industry is poised for significant expansion, with projections indicating it could reach between $230 billion and $255 billion by 2030, according to a report by McKinsey & Company. Titled “From Challenges to Possibilities: Leading India’s Chemicals Industry Through Global Headwinds,” the report highlights that the sector is expected to grow faster than the overall economy, driven by rising demand across multiple industrial segments.

Current Market Strength and Strong Financial Performance

At present, India’s chemicals industry is valued between $155 billion and $165 billion, reflecting steady and profitable growth over the past decade. Notably, Indian chemical companies have delivered an impressive 17% CAGR in total shareholder returns, outperforming global peers as well as broader market indices. This strong performance underscores the sector’s resilience and long-term growth potential.

Domestic Demand to Drive Future Expansion

Looking ahead, domestic demand will play a critical role in accelerating growth. Increasing consumption, expanding manufacturing capabilities, and the rapid rise of specialty chemicals are expected to fuel the next phase of industry expansion. Moreover, sectors such as infrastructure, automotive, electronics, and agriculture will continue to create sustained demand for chemical products.

Emerging Segments Offer New Growth Opportunities

The report highlights several high-growth segments that will shape the future of the industry. For instance, construction-related chemicals are projected to reach a market size of $28 billion by 2030, supported by India’s ongoing urbanization and infrastructure development. In addition, McKinsey & Company has identified eighteen key opportunities across the chemical value chain, which are expected to unlock new avenues for business expansion and innovation.

Trade Deficit Creates Scope for Domestic Manufacturing

The report points to a $31 billion trade deficit in chemicals, particularly in inorganic chemicals and polymer products. This gap presents a significant opportunity for Indian manufacturers to increase domestic production and reduce reliance on imports. By localizing manufacturing, companies can enhance supply chain resilience while capturing a larger share of the domestic market.

Policy Support and Investments to Boost Global Competitiveness

The industry is set to benefit from supportive government policies, increasing investments, and a favourable business environment. As a result, India’s chemicals sector is expected to strengthen its global competitiveness, positioning itself as a key player in international markets.

Outlook: A High-Growth Decade Ahead

Overall, India’s chemicals industry is entering a high-growth phase, supported by strong fundamentals, expanding demand, and strategic opportunities across the value chain. As reported by ibef.org, with continued investments and policy support, the sector is well-positioned to achieve its projected growth trajectory and play a vital role in the country’s industrial and economic development.

A severe shortage of propane, a critical fuel used for powering reactors and generating steam, has disrupted pharmaceutical manufacturing across Gujarat and key industrial clusters in Maharashtra, Telangana, and Andhra Pradesh. As a result, several pharmaceutical units have scaled down or temporarily suspended operations. This disruption is already affecting the production of essential medicines, including fever treatments, nutritional supplements, and hormone-based therapies.

Boiler-Dependent Operations Hit Hard

The crisis has significantly impacted boiler-dependent processes, which form the backbone of pharmaceutical manufacturing. Consequently, production output is declining, and companies are increasingly relying on existing inventories. However, with fuel supply renegotiations underway, concerns are mounting over potential medicine shortages in the coming weeks.

India’s API Manufacturing at Risk

India, a global hub for Active Pharmaceutical Ingredient (API) production, plays a crucial role in supplying medicines worldwide. The country’s large-scale facilities manufacture a wide range of drugs, including pain relievers, antibiotics, anti-inflammatory medicines, diabetes treatments, and essential micronutrients. However, the heavy reliance on propane for energy-intensive operations has exposed a critical vulnerability. Industry experts warn that nearly 200 pharmaceutical units could face shutdown within the next 7 to 10 days if the situation persists.

Supply Chain Disruptions and Rising Costs

The ongoing energy crisis has been further aggravated by disruptions in LNG import routes, leading to acute supply shortages and a sharp rise in gas prices. As a result, manufacturers are struggling to maintain operations amid rising input costs and shrinking margins. Experts caution that prolonged disruptions could delay production cycles, increase drug prices, and weaken India’s position in global pharmaceutical supply chains. Moreover, the impact may extend beyond medicines to essential medical supplies such as syringes and gloves.

LPG Dependence Puts Critical Drug Production at Stake

Bulk drug manufacturers have raised concerns over their dependence on LPG for key processes such as sterilization, granulation, and boiler operations. Importantly, any prolonged shortage could severely disrupt the production of life-saving drugs, particularly injectable medicines that require stringent manufacturing conditions.

Industry Seeks Government Intervention

In response to the crisis, pharmaceutical companies have urged the government to introduce relief measures. These include granting exemptions similar to those provided during the pandemic, allowing continued operations under the essential commodities category. Industry stakeholders stress the need for immediate policy support to stabilize fuel supply and ensure uninterrupted production.

Implications for Healthcare and Global Supply

If the disruption continues, experts warn of widespread implications for both domestic healthcare systems and global drug availability. As reported by moneycontrol.com, the crisis highlights the urgent need for energy diversification and supply chain resilience within India’s pharmaceutical sector to safeguard against future disruptions.

Major industrial companies, including Reliance Industries, Grasim Industries, Nirma Ltd, Gujarat Fluorochemicals, and GHCL, have received environmental clearances to discharge treated industrial effluents into the Arabian Sea along the Gujarat coast.

Collectively, these projects allow the discharge of over 460 million litres per day (MLD) of treated wastewater through marine outfall pipelines extending more than 110 km. This move reflects the growing reliance on regulated marine disposal systems for industrial wastewater management.

Key Approvals Across Major Industrial Units

Among the approved projects, Reliance Industries has secured the largest clearance for its petrochemical complex in Dahej, permitting the discharge of approximately 63 MLD of treated effluent via an offshore pipeline.

Similarly, Grasim Industries has been allowed to release 27 MLD from its Indian Rayon unit in Veraval, while Nirma Ltd has received approval to discharge 12 MLD from its soda ash plant in Bhavnagar. In addition, Gujarat Fluorochemicals at Dahej has been cleared for 3.2 MLD, and GHCL units in Kutch and Gir Somnath have received approvals for smaller discharge volumes. These details were recently shared in the Rajya Sabha by Kirti Vardhan Singh.

CETPs and Industrial Clusters Drive Large-Scale Projects

In addition to individual units, several Common Effluent Treatment Plants (CETPs) serving industrial clusters have also received approvals. For instance, the Vapi Green Environment Ltd facility has been permitted to discharge 70 MLD through a 29.68-km marine pipeline. Likewise, the Sarigam CETP expansion in Valsad allows 25 MLD of treated effluent to be released into the sea.

Furthermore, in the Petroleum, Chemicals and Petrochemicals Investment Region (PCPIR) at Dahej, a project in the SEZ-II area has been cleared to discharge about 90 MLD via a 4.3-km offshore pipeline. Another major project near Porbandar enables the release of 80 MLD of treated effluents collected from CETPs in Jetpur, Bhatgam, and Manpur–Derdi through a 5.6-km deep-sea pipeline.

Andhra Pradesh Projects Focus on Pharma Sector

Meanwhile, a smaller number of projects have been approved along the Andhra Pradesh coast, primarily linked to pharmaceutical manufacturing. Five pharma units across Srikakulam, Visakhapatnam, and Kakinada have received clearances to discharge treated effluents into the sea.

These include Divi’s Laboratories, Lyfius Pharma, Auroactive Pharma, and Shreas Industries. Together, these projects account for approximately 13.5 MLD of treated wastewater discharge through pipelines spanning around 41 km.

Regulatory Oversight and Environmental Safeguards

Importantly, authorities in both Gujarat and Andhra Pradesh have reported no violations or non-compliance cases related to these projects so far. According to the environment ministry, all marine discharge projects must undergo rigorous marine environmental impact assessments, including biodiversity monitoring and baseline ecological studies. Additionally, compliance with Coastal Regulation Zone (CRZ) norms is strictly monitored by State Coastal Zone Management Authorities.

Balancing Industrial Growth and Environmental Responsibility

Overall, these approvals highlight the increasing adoption of regulated marine outfall systems to manage industrial wastewater. At the same time, they underscore the importance of maintaining strict environmental safeguards to protect marine ecosystems.

As reported by thehindubusinessline.com, as India continues to expand its industrial base, such projects demonstrate the need to balance economic growth with sustainable environmental practices, ensuring long-term ecological and regulatory compliance.

The Indian Institute of Technology (IIT) Roorkee inaugurated the Ashok Soota Molecular Medicine Facility at its Department of Biosciences and Bioengineering (BSBE), marking a major milestone in strengthening India’s biomedical research infrastructure. The initiative aligns with national healthcare priorities while also supporting global scientific advancements in translational medicine. The facility was inaugurated by Ashok Soota, a distinguished alumnus, in the presence of Prof. K. K. Pant, Director, IIT Roorkee, along with faculty members, researchers, and industry representatives.

A State-of-the-Art Platform for Translational Biomedical Research

Designed as an integrated and advanced research platform, the Ashok Soota Molecular Medicine Facility will significantly enhance capabilities in drug discovery, biomolecular research, and next-generation diagnostics.

Importantly, the facility enables researchers to seamlessly move from understanding disease mechanisms and identifying biomolecular targets to validating lead molecules and developing assays. By integrating expertise across protein science, molecular and cell biology, structural biology, biophysics, and advanced imaging, the facility supports high-impact research. As a result, it will drive innovation across critical disease areas such as cancer, neurological disorders, metabolic diseases, and infectious diseases.

Cutting-Edge Infrastructure and Advanced Instrumentation

The facility houses a comprehensive suite of high-end instruments that support end-to-end workflows in molecular characterization and translational research. These include:

*Automated Protein Purification Systems (AKTA and Biorad/AKTA)

*HPLC and UPLC systems

*GC-MS systems

*Iso-Thermal Calorimeter (ITC)

*Flow Cytometer

*Upright Confocal Microscope

*Small-Angle X-ray Scattering (SAXS)

Protein Crystallization Robot

*CD Spectrometer

*High-Pressure Homogenizer/Cell Disruptor

Together, these advanced analytical platforms significantly strengthen IIT Roorkee’s capabilities in molecular diagnostics, biomolecular interaction studies, structural validation, and assay development.

Accelerating Innovation in Healthcare and Precision Medicine

Pant emphasized that the facility will substantially enhance the institute’s research ecosystem. He highlighted that integrating advanced infrastructure with interdisciplinary expertise will accelerate translational research and contribute to national priorities such as healthcare innovation, precision medicine, and scientific self-reliance.

Strengthening Research Ecosystems and Industry Collaboration

Ashok Soota underscored the importance of building robust research ecosystems that translate scientific discoveries into real-world impact. He noted that while India has immense scientific talent, it is equally important to provide world-class infrastructure and collaborative platforms to enable innovation at scale. Furthermore, he expressed confidence that the facility will enhance capabilities in molecular diagnostics, precision medicine, and drug discovery, contributing to both national and global healthcare solutions.

A Collaborative Hub for Interdisciplinary Research

Pravindra Kumar, Head of the Institute Instrumentation Center and Ashok Soota Institute Chair Professor, highlighted that the facility will serve as a shared research platform for faculty, scholars, and industry partners. Consequently, it will strengthen IIT Roorkee’s ability to undertake globally competitive, interdisciplinary research in molecular medicine and translational biosciences.

Driving India’s Future in Biomedical Innovation

With this strategic initiative, Indian Institute of Technology Roorkee continues to reinforce its commitment to advancing interdisciplinary research and fostering industry collaboration. As per the press release, the Ashok Soota Molecular Medicine Facility positions the institute at the forefront of innovation, enabling cutting-edge solutions that address critical challenges in both national and global healthcare systems.